As work started on its new $1.8 billion diabetes medicine production facility in Clayton, North Carolina, Project Director Gary Lohr spoke about the significance of the huge investment for Novo Nordisk (NOV:N).
He also told The Pharma Letter that it reflected strategic advantages of pharma companies basing manufacturing facilities in the USA.
Founded and headquartered in Denmark and with 90 years of experience in leading diabetes care, the building of a facility producing Novo Nordisk’s active pharmaceutical ingredients (API) for current and future GLP-1 and insulin medicines across the Atlantic shows the company’s confidence in the US market.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze